Global, Regional, and National Burdens of Ischemic Stroke Attributed to High Body-mass Index from 1990 to 2021

Yuan Zhang; Xuesong Ren; Xiaofeng Zhao; Lina Meng; Hai Lu; Chunhong Zhang

doi:10.1101/2024.10.20.24315842

Abstract

Background Ischemic stroke (IS) is a significant contributor to the global disease burden, with overweight/obesity recognized as one of the primary risk factors. This study aims to evaluate the distribution and changes in the global burden of IS attributable to high body-mass index (BMI) from 1990 to 2021, providing a foundation for the development of targeted prevention and treatment strategies.

Methods Based on the modeling strategies of the 2021 global burden of disease (GBD) dataset, the burden of IS attributable to high BMI was estimated. The assessment covered the global disease burden and its distribution by region, country, development level, age group, and gender, as well as temporal trends. Age-standardized rates, along with the estimated annual percentage change (EAPC) in these rates, were utilized to describe this burden and its evolving trends. Locally estimated scatterplot smoothing (LOESS) regression was employed to analyze the trends of disease burden in relation to changes in socio-demographic index (SDI).

Results From 1990 to 2021, although the age-standardized death rate and disability-adjusted life years (DALY) rate for IS attributable to high BMI have declined globally, the absolute number of deaths and DALYs nearly doubled, reaching 172,390.65 (95% UI, 347,912.75 to 25,064.57) and 4,439,186.31 (95% UI, 8,647,485.11 to 649,030.21) respectively. Meanwhile, significant disparities in disease burden existed across different regions, genders, and age groups. In high-middle SDI regions, the burden of IS caused by high BMI significantly exceeded that in other regions, while in low-income areas, this burden was rapidly increasing. Additionally, the increase in burden among men was significantly greater than that among women, and the previously concentrated burden in the elderly is now rapidly shifting toward younger groups.

Conclusions The overweight and obese populations continue to present significant challenges in managing the burden of IS. In light of future population growth and aging trends, more effective stroke prevention strategies and practical solutions are urgently needed, particularly in low- and middle-income countries. Additionally, given the increasing disease burden among men and younger populations, it is essential to establish targeted preventive measures to address the specific needs of different groups and improve overall health outcomes.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This study is neither a clinical trial nor any other prospective intervention study, therefore, it has not been registered in an internationally recognized trial registry.

Funding Statement

This study was supported by National Key R&D Program (Grant number 2018YFE181700); National Natural Science Foundation of China (Grant number 82305402); China Postdoctoral Science Foundation funded project of the China Postdoctoral Science Foundation (Grant number 2022M711590); Scientific research project of Hebei Province Administration of Traditional Chinese Medicine (Grant number T2025097).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study followed the Guidelines for Accurate and Transparent Health Estimation Reporting that define best practices for studies that calculate health estimates for multiple populations, and informed consent was not required.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from: https://vizhub.healthdata.org/gbd-results/. Analysis codes can be obtained by contacting the corresponding author.